Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Kavita Patel Biography and Net Worth

Director of Arcellx

Dr. Kavita Patel is currently a primary care physician in Washington DC. She is also a nonresident Fellow at the Brookings Institution where she concentrates on a number of efforts including delivery system reforms and cost containment. Recently, she was a system level executive at Johns Hopkins Health System with oversight of clinical integration and network contracting . Dr. Patel was previously a Director of Policy for The White House under President Obama and a Deputy Staff Director to the late Senator Edward Kennedy, where she focused on pandemic preparedness and health care reform. Her prior research in healthcare quality and community approaches to mental illness have earned national recognition and she has published numerous papers and book chapters on healthcare reform and health policy.

How do I contact Kavita Patel?: The corporate mailing address for Dr. Patel and other Arcellx executives is , , . Arcellx can also be reached via phone at 240-327-0603 and via email at [email protected]. Learn More on Kavita Patel's contact information.
Has Kavita Patel been buying or selling shares of Arcellx?: During the last ninety days, Kavita Patel has sold $5,264,622.78 in shares of Arcellx stock. Most recently, Kavita Patel sold 15,238 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $105.92, for a transaction totalling $1,614,008.96. Learn More on Kavita Patel's trading history.
Who are Arcellx's active insiders?: Arcellx's insider roster includes Jill Carroll (Director), Rami Elghandour (Chairman and Chief Executive Officer), Michelle Gilson (CFO), Christopher Heery (Chief Medical Officer), Kavita Patel (Director), Olivia Ware (Director), and Olivia Ware (Director). Learn More on Arcellx's active insiders.
Are insiders buying or selling shares of Arcellx?: In the last year, insiders at the sold shares 29 times. They sold a total of 852,221 shares worth more than $59,596,182.56. The most recent insider tranaction occured on November, 11th when Director Kavita Patel sold 15,238 shares worth more than $1,614,008.96. Insiders at Arcellx own 6.2% of the company. Learn More about insider trades at Arcellx.
Information on this page was last updated on 11/11/2024.

Kavita Patel Insider Trading History at Arcellx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/11/2024	Sell	15,238	$105.92	$1,614,008.96
11/8/2024	Sell	33,763	$104.14	$3,516,078.82
10/22/2024	Sell	1,500	$89.69	$134,535.00
9/10/2024	Sell	1,500	$74.41	$111,615.00
7/30/2024	Sell	1,500	$61.97	$92,955.00
7/9/2024	Sell	1,500	$56.63	$84,945.00
6/27/2024	Sell	10,000	$54.27	$542,700.00

Kavita Patel Buying and Selling Activity at Arcellx

Arcellx Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $87.22

$83.69

$88.30

50 Day Range

MA: $86.52

$74.40

$106.53

2 Week Range

Now: $87.22

$46.42

$107.37

Volume

344,951 shs

Average Volume

481,359 shs

Market Capitalization

$4.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27